Insider · CIK 0001753224
Thomas Gad
Files at YMAB (Y-mAbs Therapeutics, Inc.). First filing Mar 11, 2025, latest Mar 11, 2025.
In brief
Thomas Gad files SEC Form 4 as officer and director at YMAB (Y-mAbs Therapeutics, Inc.). Since Mar 11, 2025, Thomas Gad has reported 0 open-market buys worth $0 and 1 open-market sell worth $57k, the latest filed on Mar 11, 2025.
A track record needs three past buys with six months of prices behind them; Thomas Gad has 0, so none is measured yet.
The newest scored trade: sold $57k of YMAB on Mar 7, 2025, filed Mar 11, 2025, scored 22 (weak).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 22Weak | YMABsell Y-mAbs Therapeutics, Inc. | $57k 10,810 shares | -5% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 7, 2025 | YMAB Y-mAbs Therapeutics, Inc. | 10,810 0.02% of outstanding | $57k | Mar 7, 2025 | none |
Transactions
Every row this insider has filed, 23 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | UTender of shares Common Stock | -245,486 | $8.60 | $2.1M | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Common Stock | -60,235 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | UTender of shares Common Stockindirect: By GAD Enterprises LLC | -67,681 | $8.60 | $582k | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | UTender of shares Common Stockindirect: By Children | -60,000 | $8.60 | $516k | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -143,169 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -16,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -100,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -107,500 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -130,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -91,450 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -110,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -60,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -242,200 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -75,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -132,500 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -64,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Restricted Stock Unitsderivative | -16,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Restricted Stock Unitsderivative | -16,000 | - | - | 0 | Sep 18, 2025 |
| Jun 3, 2025 | YMAB Y-mAbs Therapeutics, Inc. | MOption exercise Common Stock | +103,000 | $2.00 | $206k | 305,721 | Jun 5, 2025 |
| Jun 3, 2025 | YMAB Y-mAbs Therapeutics, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -103,000 | $0.00 | $0 | 0 | Jun 5, 2025 |
| Mar 7, 2025 | YMAB Y-mAbs Therapeutics, Inc. | SOpen-market sale Common Stock | -10,810 | $5.23 | $57k | 202,721 | Mar 11, 2025 |
| Jan 17, 2025 | YMAB Y-mAbs Therapeutics, Inc. | AGrant or award Common Stock | +32,000 | $0.00 | $0 | 213,531 | Jan 22, 2025 |
| Jan 17, 2025 | YMAB Y-mAbs Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +64,000 | $0.00 | $0 | 64,000 | Jan 22, 2025 |
Questions about Thomas Gad
Answered from the filings on this page, as of the latest one.
Is Thomas Gad buying or selling?
Not in the last 12 months. Thomas Gad's latest open-market trade on SEC Form 4 was sold $57k of YMAB on Mar 7, 2025.
How did Thomas Gad's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Thomas Gad has 0.
Where does Thomas Gad file Form 4?
Thomas Gad has filed Form 4 at YMAB (Y-mAbs Therapeutics, Inc.) as CHIEF BUSINESS OFFICER. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.